Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.04.02 | Steroids | ECE2015

The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure

Sherlock Mark , Behan Lucy Ann , Hannon Mark , Alonso Aurora Aragon , Thompson Christopher , Murray Robert , Crabtree Nicola , Hughes Beverly , Arlt Wiebke , Agha Amar , Toogood Andrew , Stewart Paul M

Context: Patients with hypopituitarism have increased morbidity and mortality. There is ongoing debate around the optimum glucocorticoid replacement therapy.Objective: To assess the effect of glucocorticoid replacement in hypopituitarism on corticosteroid metabolism and its impact on body composition.Design and patients: We assessed the urinary corticosteroid metabolite profile (using gas chromatography/mass spectrometry) and body ...

ea0037gp.04.04 | Steroids | ECE2015

Regulation of lipogenesis in human hepatocytes by androgens, glucocorticoids, and 5α-reductase

Nikolaou Nikolaos , Nasiri Maryam , Parajes Sylvia , Krone Nils , Mastorakos George , Valsamakis George , Hughes Beverly , Taylor Angela , Bujalska Iwona , Gathercole Laura , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the commonest cause of liver cirrhosis and leading indication for liver transplant worldwide. It is tightly associated with obesity and type 2 diabetes, yet the precise mechanisms that drive its aetiology are not fully defined. Dysregulation of both glucocorticoid and androgen metabolism has been implicated in its pathogenesis. The availability of these hormones to bind and activate their receptors is mainly regulat...

ea0033oc1.7 | Oral Communications 1 | BSPED2013

A mutation in thioredoxin reductase 2 is associated with familial glucocorticoid deficiency

Prasad Rathi , Chan Li , Hughes Claire , Kaski Juan , Kowalczyk Julia , Savage Martin , Peters Catherine , Nathwani Nisha , Clark Adrian , Storr Helen , Metherell Louise

Background: Novel pathogenic mechanisms involving replicative and oxidative stress have recently been described in familial glucocorticoid deficiency (FGD); including mutations in NNT. NNT supplies high concentrations of NADPH needed by the glutathione and thioredoxin anti-oxidant systems to detoxify mitochondrial H2O2.Six patients, from a consanguineous Kashmiri family, were diagnosed with glucocorticoid deficiency between...

ea0032p841 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

The benefits of pasireotide in patients with Cushing's disease are not restricted to patients with normalisation of UFC; results from a large, 12-month study

Pivonello Rosario , Petersenn Stephan , Gu Feng , Trovato Andrew , Hughes Gareth , Ligueros-Saylan Monica , Roberto Salgado Luiz , Lacroix Andre , Schopohl Jochen , Biller Beverly

Introduction: Pasireotide normalized or reduced UFC in patients with Cushing’s disease in a large, 12-month study. This analysis evaluates the effects of pasireotide on the signs/symptoms of Cushing’s disease according to the degree of UFC control.Methods: Adult patients (n=162) with persistent/recurrent or de novo Cushing’s disease were randomized to pasireotide 600/900 μg s.c. bid. Dose titration (max: 1200 μg...

ea0029p1406 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large phase III study in Cushing’s disease

Pivonello R , Petersenn S , Newell-Price J , Gu F , Maldonado M , Trovato A , Hughes G , Salgado L , Lacroix A , Schopohl J , Biller B

Introduction: Patients with Cushing’s disease (CD) have an increased risk of hypertension (HTN). phase III data have shown that pasireotide leads to rapid reductions in UFC levels and significant improvements in CD symptoms. We now present further analyses of these data, evaluating the effects of pasireotide on HTN in patients with CD.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) CD and UFC≥1.5 time...

ea0019p337 | Steroids | SFEBES2009

The role of serum and urinary steroids in the monitoring of adults with congenital adrenal hyperplasia

Reisch N , Krone N , Hughes B A , Vassiliadi D A , Flade L , Bidlingmaier M , Shackleton C H L , Stewart P M , Arlt W

Glucocorticoid treatment in congenital adrenal hyperplasia (CAH) is a continuous challenge, with even the experienced clinician struggling to strike the right balance between glucocorticoid over- and undertreatment. There is no consensus on monitoring of glucocorticoid therapy in adults with CAH. Some recommend a serum 17-hydroxyprogesterone (17OHP) target range of 12–36 nmol/l prior to glucocorticoid morning dose. Here we investigated the value of serum and urinary stero...

ea0015oc16 | Reproduction | SFEBES2008

Enhanced hypothalamic–pituitary–adrenal axis activation, 5α-reductase activity and insulin resistance distinguishes polycystic ovary syndrome from simple obesity

Vassiliadi Dimitra A , Tomlinson Jeremy W , Hughes Beverly A , Gay Christopher , Sira Shaleen , Nightingale Peter , Shackleton Cedric HL , Stewart Paul M , Arlt Wiebke

Polycystic ovary syndrome (PCOS) affects 5–10% of the female population. It is characterised by androgen excess and anovulatory infertility; several studies have reported an increased incidence of the metabolic syndrome and enhanced 5α-reductase activity in PCOS. However, the contribution of obesity to these findings has yet to be clarified. Here we have analysed metabolic status and urinary steroid metabolite excretion in 114 patients with PCOS (median age 30 (range...

ea0015p186 | Endocrine tumours and neoplasia | SFEBES2008

A succinate dehydrogenase B (SDHB) founder mutation

Hughes Katherine , McDougall Lindsay , Bradshaw Nicola , Perry Colin , Lindsay Robert , McConachie Michelle , Davidson D Fraser , Murday Victoria , Connell John M C

Phaeochromocytomas (PHAEO)/paragangliomas (PGL) are neuro-endocrine tumours. They may present sporadically or as the primary abnormality in a number of familial syndromes. Advances in molecular genetics have led to the identification of several PHAEO/PGL predisposing genes including VHL, NF1 and RET. Mutations in the genes encoding the subunits of Succinate Dehydrogenase (SDH) have also been reported. We describe the phenotype of a cohort of patients with a Succinate Dehydroge...

ea0015p204 | Neuroendocrinology and behaviour | SFEBES2008

Increased desire for food when fasted is associated with increased activation of the ventral striatum, insula and amygdala in humans

Goldstone Anthony P , de Hernandez Christina Prechtl , Muhammed Kinan , Bell Gabriel , Durighel Giuliana , Hughes Emer , Waldman Adam D , Bell Jimmy D

Using functional MRI, we examined how regional brain activity varies with nutritional state when viewing food pictures of different caloric density and appeal.Eighteen non-obese healthy volunteers (BMI 22.2±0.5 kg/m2, age range 19–36 years, 8 male) were studied on 2 separate mornings after an overnight fast (mean±S.E.M. 15.5±0.3 h) or when fed (1.2±0.1 h after breakfast, food intake 45±4% of estimat...

ea0013p193 | Diabetes, metabolism and cardiovascular | SFEBES2007

Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese children

Wiegand Susanna , Richardt Anna , Remer Thomas , Wudy Stefan A , Tomlinson Jeremy W , Hughes Beverly , Grüters Annette , Stewart Paul M , Strasburger Christian J , Quinkler Marcus

Objective: The incidence of childhood obesity and type 2 diabetes has reached epidemic proportions. Glucocorticoid excess causes central obesity and diabetes mellitus as seen in Cushing’s syndrome. The 11beta-hydroxysteroid dehydrogenase type 1 enzyme (11beta-HSD1), which is predominantly expressed in liver and adipose tissue, regenerates active cortisol from inactive cortisone. Altered 11beta-HSD1 may cause tissue-specific Cushing syndrome with central obesity and impair...